Becker's Healthcare January 24, 2025
As norovirus cases increase across the U.S., Moderna is conducting a phase 3 trial with 25,000 participants to test its experimental vaccine, CNBC reported.
The vaccine manufacturer is recruiting for the study across the U.S., Canada, U.K., Japan, the equatorial region, Australia and countries in South America. About 20,000 trial subjects will be ages 60 and up, and the other 5,000 will be between 18 and 59 years old.
On Sept. 30, Moderna said it had dosed the first participant in the trial evaluating the candidate, mRNA-1403.
The company expects results to be available in late 2025 or early 2026, according to CNBC.
Doran Fink, MD, PhD, Moderna’s clinical therapeutic area head of gastrointestinal and bacterial...
Today's Sponsors
Today's Sponsor